Effects of prolonged ethanol vapor exposure on forced swim behavior, and neuropeptide Y and corticotropin-releasing factor levels in rat brains

Alcohol

Volumn 44, Issue 6, 2010, Pages 487-493

  Walker, Brendan M ^a   Drimmer, David A ^a   Walker, Jennifer L ^a   Liu, Tianmin ^b   Mathé, Aleksander A ^b   Ehlers, Cindy L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alcohol; CRF; Dependence; Depression; Forced swim test; NPY

Indexed keywords

ALCOHOL; CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE Y;

ALCOHOL WITHDRAWAL; ALCOHOLISM; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CLIMBING; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; NONHUMAN; RAT; VAPORIZATION; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; ETHANOL; IMMOBILITY RESPONSE, TONIC; LATENCY PERIOD (PSYCHOLOGY); MALE; NEUROPEPTIDE Y; RATS; RATS, WISTAR; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME; SWIMMING; VOLATILIZATION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 77956647916     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.alcohol.2010.06.006     Document Type: Article

References (60)

1. Breese G.R., Knapp D.J., Overstreet D.H. Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonists and a 5-HT1A-receptor agonist. Neuropsychopharmacology 2004, 29:470-482.
2. Breese G.R., Overstreet D.H., Knapp D.J., Navarro M. Prior multiple ethanol withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1- and benzodiazepine-receptor antagonists and a 5-HT1a-receptor agonist. Neuropsychopharmacology 2005, 30:1662-1669.
3. Brown S.A., Schuckit M.A. Changes in depression among abstinent alcoholics. J. Stud. Alcohol 1988, 49:412-417.
4. Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., et al. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. 2004, 485:145-158.
5. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
6. Ehlers C.L., Li T.K., Lumeng L., Hwang B.H., Somes C., Jimenez P., et al. Neuropeptide Y levels in ethanol-naive alcohol-preferring and nonpreferring rats and in Wistar rats after ethanol exposure. Alcohol. Clin. Exp. Res. 1998, 22:1778-1782.
7. Funk C.K., O'Dell L.E., Crawford E.F., Koob G.F. Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J. Neurosci. 2006, 26:11324-11332.
8. Funk C.K., Zorrilla E.P., Lee M.J., Rice K.C., Koob G.F. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol. Psychiatry 2007, 61:78-86.
9. Gilder D.A., Wall T.L., Ehlers C.L. Comorbidity of select anxiety and affective disorders with alcohol dependence in southwest California Indians. Alcohol. Clin. Exp. Res. 2004, 28:1805-1813.
10. Gilpin N.W., Misra K., Koob G.F. Neuropeptide Y in the central nucleus of the amygdala suppresses dependence-induced increases in alcohol drinking. Pharmacol. Biochem. Behav. 2008, 90:475-480.
11. Grant B.F., Harford T.C. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995, 39:197-206.
12. Hasin D.S., Grant B.F. Major depression in 6050 former drinkers: association with past alcohol dependence. Arch. Gen. Psychiatry 2002, 59:794-800.
13. Heilig M., Koob G.F. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007, 30:399-406.
14. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989, 98:524-529.
15. Heinrichs S.C., Menzaghi F., Pich E.M., Baldwin H.A., Rassnick S., Britton K.T., et al. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 1994, 11:179-186.
16. Holmes A., Heilig M., Rupniak N.M., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 2003, 24:580-588.
17. Husum H., Mathé A.A. Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 2002, 27:756-764.
18. Jimenez-Vasquez P.A., Diaz-Cabiale Z., Caberlotto L., Bellido I., Overstreet D., Fuxe K., et al. Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur. Neuropsychopharmacol. 2007, 17:298-308.
19. Kessler R.C., Crum R.M., Warner L.A., Nelson C.B., Schulenberg J., Anthony J.C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch. Gen. Psychiatry 1997, 54:313-321.
20. Khantzian E.J. Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences. Recent Dev. Alcohol. 1990, 8:255-271.
21. Knapp D.J., Overstreet D.H., Breese G.R. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol. Clin. Exp. Res. 2007, 31:582-595.
22. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 2008, 28:407-414.
23. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 1997, 8:523-532.
24. Madaan V., Wilson D.R. Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug News Perspect. 2009, 22:319-324.
25. Markou A., Kosten T.R., Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18:135-174.
26. Mathé A.A., Gruber S., Jimenez P.A., Theodorsson E., Stenfors C. Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain. Neurochem. Res. 1997, 22:629-636.
27. Mathé A.A., Husum H., El K.A., Jimenez-Vasquez P., Gruber S.H., Wortwein G., et al. Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?. Physiol. Behav. 2007, 92:226-231.
28. Mathé A.A., Jimenez P.A., Theodorsson E., Stenfors C. Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn Hooded " depressed" , Wistar, and Sprague Dawley rats. Effects of electroconvulsive stimuli. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22:529-546.
29. Mathé A.A., Rudorfer M.V., Stenfors C., Manji H.K., Otter W.C., Theodorsson E. Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin and neurokinin A concentrations in cerebrospinal fluid of depressed patients. Depression 1996, 3:250-257.
30. Merlo P.E., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 1995, 15:5439-5447.
31. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol. 2005, 8:403-410.
32. Nikisch G., Mathé A.A. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur. Psychiatry 2008, 23:356-359.
33. O'Dell L.E., Roberts A.J., Smith R.T., Koob G.F. Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol. Clin. Exp. Res. 2004, 28:1676-1682.
34. O'Sullivan K. Depression and its treatment in alcoholics: a review. Can. J. Psychiatry 1984, 29:379-384.
35. Overstreet D.H., Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur. J. Pharmacol. 2004, 497:49-53.
36. Overstreet D.H., Knapp D.J., Breese G.R. Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol. Clin. Exp. Res. 2002, 26:1259-1268.
37. Palkovits M., Brownstein M.J. Maps and guide to microdissection of the rat brain 1988, Elsevier, New York, NY.
38. Paschos K.A., Veletza S., Chatzaki E. Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression. CNS Drugs 2009, 23:755-772.
39. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 1993, 605:25-32.
40. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
41. Redrobe J.P., Dumont Y., Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci. 2002, 71:2921-2937.
42. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
43. Rimondini R., Sommer W., Heilig M. A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. J. Stud. Alcohol 2003, 64:445-449.
44. Roberts A.J., Cole M., Koob G.F. Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol. Clin. Exp. Res. 1996, 20:1289-1298.
45. Roberts A.J., Heyser C.J., Cole M., Griffin P., Koob G.F. Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 2000, 22:581-594.
46. Rogers J., Wiener S.G., Bloom F.E. Long-term ethanol administration methods for rats: advantages of inhalation over intubation or liquid diets. Behav. Neural Biol. 1979, 27:466-486.
47. Roy A., DeJong J., Lamparski D., George T., Linnoila M. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch. Gen. Psychiatry 1991, 48:428-432.
48. Schuckit M.A., Tipp J.E., Bergman M., Reich W., Hesselbrock V.M., Smith T.L. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am. J. Psychiatry 1997, 154:948-957.
49. Schuckit M.A., Tipp J.E., Bucholz K.K., Nurnberger J.I., Hesselbrock V.M., Crowe R.R., et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 1997, 92:1289-1304.
50. Slawecki C.J., Thorsell A., Ehlers C.L. Long-term neurobehavioral effects of alcohol or nicotine exposure in adolescent animal models. Ann. N. Y. Acad. Sci. 2004, 1021:448-452.
51. Sommer W.H., Rimondini R., Hansson A.C., Hipskind P.A., Gehlert D.R., Barr C.S., et al. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol. Psychiatry 2008, 63:139-145.
52. Stenfors C., Mathé A.A., Theodorsson E. Repeated electroconvulsive stimuli: changes in neuropeptide Y, neurotensin and tachykinin concentrations in time. Prog. Neuropsychopharmacol. Biol. Psychiatry 1994, 18:201-209.
53. Stenfors C., Theodorsson E., Mathé A.A. Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. J. Neurosci. Res. 1989, 24:445-450.
54. Stogner K.A., Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 2000, 387:R9-R10.
55. Thorsell A., Slawecki C.J., Ehlers C.L. Effects of neuropeptide Y and corticotropin-releasing factor on ethanol intake in Wistar rats: interaction with chronic ethanol exposure. Behav. Brain Res. 2005, 161:133-140.
56. Valdez G.R., Roberts A.J., Chan K., Davis H., Brennan M., Zorrilla E.P., et al. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol. Clin. Exp. Res. 2002, 26:1494-1501.
57. Walker B.M., Koob G.F. The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol. Clin. Exp. Res. 2007, 31:11-18.
58. Walker B.M., Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008, 33:643-652.
59. Zambello E., Jimenez-Vasquez P.A., El K.A., Mathé A.A., Caberlotto L. Acute stress differentially affects corticotropin-releasing hormone mRNA expression in the central amygdala of the " depressed" flinders sensitive line and the control flinders resistant line rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:651-661.
60. Zorrilla E.P., Valdez G.R., Weiss F. Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 2001, 158:374-381.